Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
IRVINE, Calif., May 06, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO). Investors who purchased or otherwise acquired shares between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 13, 2017 lead plaintiff motion deadline.
If you purchased Lion shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that throughout the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that Lion, through its former Chief Executive Officer (“CEO”) Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times. When this information was released to the public, Lion’s stock price dropped materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
